Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 3, 2009, Pages 467-476

  Giaccone, Giuseppe ^a   Iacona, Renee B ^b   Fandi, Abderrahim ^b,c,d   Janas, Mette ^e,f   Ochs, Judith S ^b   Herbst, Roy S ^g   Johnson, David H ^h  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ASTRAZENECA   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF TURIN   (Italy)

^e Dako   (Denmark)

^f Leo Pharma   (Denmark)

^g UNIVERSITY OF TEXAS   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Chemotherapy; EGFR; Gefitinib; Immunohistochemistry; NSCLC; Tumor biopsies

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PLACEBO; PLATINUM COMPLEX;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NEOPLASM STAGING; PLACEBOS; PLATINUM COMPOUNDS; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 59449110169     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0466-3     Document Type: Article

References (36)

1. Andersen FG, Jensen SS, Pii K, Spaulding BO (2004) Characterization of a new monoclonal antibody, clone 2-18C9, for the measurement of epidermal growth factor receptor expression in solid tumours. Proc Am Assoc Cancer Res, vol 45
2. Bailey LR, Kris M, Wolf M, Kay A, Averbuch S, Askaa J, Janas M, Schmidt K, Fukuoka M (2003) Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res, vol 44 (2nd edn):1362, abs LB-170
3. DW Bell TJ Lynch SM Haserlat PL Harris RA Okimoto BW Brannigan DC Sgroi B Muir MJ Riemenschneider RB Iacona AD Krebs DH Johnson G Giaccone RS Herbst C Manegold M Fukuoka MG Kris J Baselaga JS Ochs DA Haber 2005 Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials J Clin Oncol 23 8081 8092
4. L Bingle SS Cross AS High WA Wallace DA Devine S Havard MA Campos CD Bingle 2005 SPLUNC1 (PLUNC) is expressed in glandular tissues of the respiratory tract and in lung tumours with a glandular phenotype J Pathol 205 491 497
5. J Brabender KD Danenberg R Metzger PM Schneider J Park D Salonga AH Holscher PV Danenberg 2001 Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival Clin Cancer Res 7 1850 1855
6. F Cappuzzo FR Hirsch E Rossi S Bartolini GL Ceresoli L Bemis J Haney S Witta K Danenberg I Domenichini V Ludovini E Magrini V Gregorc C Doglioni A Sidoni M Tonato WA Franklin L Crino PA Bunn Jr M Varella-Garcia 2005 Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 643 655
7. F Cappuzzo E Magrini GL Ceresoli S Bartolini E Rossi V Ludovini V Gregorc C Ligorio A Cancellieri S Damiani A Spreafico CT Paties L Lombardo C Calandri G Bellezza M Tonato L Crinò 2004 Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer J Natl Cancer Inst 96 1133 1141
8. DA Eberhard BE Johnson LC Amler AD Goddard SL Heldens RS Herbst WL Ince PA Janne T Januario DH Johnson P Klein VA Miller MA Ostland DA Ramies D Sebisanovic JA Stinson YR Zhang S Seshagiri KJ Hillan 2005 Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 5900 5909
9. U Gatzemeier A Pluzanska A Szczesna E Kaukel J Roubec F De Rosa J Milanowski H Karnicka-Mlodkowski M Pesek P Serwatowski R Ramlau T Janaskova J Vansteenkiste J Strausz GM Manikhas J von Pawel 2007 Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 1545 1552
10. J Gawrychowski A Gabriel B Lackowska 2003 Heterogeneity of stage IIIA non-small cell lung cancers (NSCLC) and evaluation of late results of surgical treatment Eur J Surg Oncol 29 178 184
11. G Giaccone RS Herbst C Manegold G Scagliotti R Rosell V Miller RB Natale JH Schiller J von Pawel A Pluzanska U Gatzemeier J Grous JS Ochs SD Averbuch MK Wolf P Rennie A Fandi DH Johnson 2004 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 777 784
12. RS Herbst G Giaccone JH Schiller RB Natale V Miller C Manegold G Scagliotti R Rosell I Oliff JA Reeves MK Wolf AD Krebs SD Averbuch JS Ochs J Grous A Fandi DH Johnson 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 785 794
13. RS Herbst D Prager R Hermann L Fehrenbacher BE Johnson A Sandler MG Kris HT Tran P Klein X Li D Ramies DH Johnson VA Miller 2005 TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 5892 5899
14. FR Hirsch M Varella-Garcia PA Bunn Jr WA Franklin R Dziadziuszko N Thatcher A Chang P Parikh J Rodrigues Pereira T Ciuleanu J von Pawel C Watkins A Flannery G Ellison E Donald L Knight D Parums N Botwood B Holloway 2006 Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 24 5034 5042
15. International Conference on Harmonisation 2001 ICH harmonised tripartite guideline: guideline for good clinical practice J Postgrad Med 47 199 203
16. JP Kallio P Hirvikoski H Helin P Kellokumpu-Lehtinen T Luukkaala TL Tammela PM Martikainen 2003 Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma Br J Cancer 89 1266 1269
17. Kishi K, Homma S, Miyamoto A, Sakamoto S, Motoi N, Yoshimura K (2005) Factors predicting the efficacy of gefitinib in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 23:644s, abs 7095
18. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan PL Harris SM Haserlat JG Supko FG Haluska DN Louis DC Christiani J Settleman DA Haber 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139
19. AP Meert B Martin P Delmotte T Berghmans JJ Lafitte C Mascaux M Paesmans E Steels JM Verdebout JP Sculier 2002 The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis Eur Respir J 20 975 981
20. AS Merseburger J Hennenlotter P Simon S Kruck E Koch M Horstmann U Kuehs R Kufer A Stenzl MA Kuczyk 2005 Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer Anticancer Res 25 1901 1907
21. Y Nakayama K Hayakawa N Mitsuhashi Y Saito H Niibe 1997 Long-term survivors of non-small cell lung cancer after radiation therapy: the significance of histological type Anticancer Res 17 2769 2773
22. RI Nicholson JMW Gee ME Harper 2001 EGFR and cancer prognosis Eur J Cancer 37 Suppl 4 S9 S15
23. Y Ohsaki S Tanno Y Fujita E Toyoshima S Fujiuchi Y Nishigaki S Ishida A Nagase N Miyokawa S Hirata K Kikuchi 2000 Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression Oncol Rep 7 603 607
24. Organisation for Economic Co-operation and Development (2007) OECD series on principles of good laboratory practice and compliance monitoring (accessed 2 May 2007, through http://www.oecd.org/document/63/0,2340,en-2649-34381-2346175- 1-1-1-1,00.html )
25. JG Paez PA Jänne JC Lee S Tracy H Greulich S Gabriel P Herman FJ Kaye N Lindeman TJ Boggon K Naoki H Sasaki Y Fujii MJ Eck WR Sellers BE Johnson M Meyerson 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500
26. SJ Pocock R Simon 1975 Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 103 115
27. DS Salomon R Brandt F Ciardiello N Normanno 1995 Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 183 232
28. FA Shepherd PJ Rodrigues T Ciuleanu EH Tan V Hirsh S Thongprasert D Campos S Maoleekoonpiroj M Smylie R Martins M van Kooten M Dediu B Findlay D Tu D Johnston A Bezjak G Clark P Santabarbara L Seymour 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132
29. DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith WJ Levin SG Stuart J Udove A Ullrich 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712
30. R Sordella DW Bell DA Haber J Settleman 2004 Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 1163 1167
31. DC Spaulding BO Spaulding 2002 Epidermal growth factor receptor expression and measurement in solid tumors Semin Oncol 29 45 54
32. N Thatcher A Chang P Parikh PJ Rodrigues T Ciuleanu J von Pawel S Thongprasert EH Tan K Pemberton V Archer K Carroll 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527 1537
33. M-S Tsao A Sakurada J-C Cutz C-Q Zhu S Kamel-Reid J Squire I Lorimer T Zhang N Liu M Daneshmand P Marrano G da Cunha Santos A Lagarde F Richardson L Seymour M Whitehead K Ding J Pater FA Shepherd 2005 Erlotinib in lung cancer-molecular and clinical predictors of outcome N Engl J Med 353 133 144
34. D Veale N Kerr GJ Gibson PJ Kelly AL Harris 1993 The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival Br J Cancer 68 162 165
35. M Volm W Rittgen P Drings 1998 Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas Br J Cancer 77 663 669
36. JR Woodburn 1999 The epidermal growth factor receptor and its inhibition in cancer therapy Pharmacol Ther 82 241 250